CANCER
Sara Cooper, PhD, Faculty Investigator , and her laboratory are experts at understanding the genetic contributors behind many types of cancer, including breast, ovarian, pancreatic, colorectal, and prostate cancer. Dr. Cooper’s team discovered that overexpression of a gene called ANGPLT4 is closely linked with chemo-resistance and metastasis in pancreatic cancer. Identifying drug treatments that target ANGPTL4 could reverse chemo-resistance and provide a much-needed therapeutic option for cancer patients. Dr. Cooper and her team have also
applied CRISPR technology to test the impact of thousands of genes on chemo- resistance. This study has led to the identification of three new genes that are being explored to identify potential drug targets in ovarian cancer. Dr. Cooper’s ovarian cancer research is supported by Rosie’s Mexican Cantina , Presenting Sponsor for our annual Tie the Ribbons luncheon .
Sara Cooper, PhD Faculty investigator
Using genomic technologies, we can untangle the genetic reasons behind treatment-resistant can- cers using an unbiased approach. Equipped with those discoveries, we can better understand how patients will respond to existing treatments and identify targets for new drugs that could improve response and increase patient survival. — Sara Cooper, PhD HudsonAlpha Faculty Investigator
Made with FlippingBook - Online magazine maker